HanAll Biopharma Reports Full-Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
Immunovant, Inc. (IMVT)
Company Research
Source: Yahoo! Finance
R&D momentum persisted with promising developments in anti-FcRn antibodies HL161ANS and batoclimab, positioning them as potentially best-in-class treatments for lgG-mediated autoimmune diseases. Anticipates the initiation of tanfanercept Phase 3 VELOS-4 study in dry eye disease in the first half of 2024 and top-line data results from HL192 Phase 1 study for Parkinson's Disease in the second half of 2024. ROCKVILLE, Md. and SEOUL, South Korea March 21, 2024 /PRNewswire/ -- HanAll Biopharma Co., Ltd. (KRX: 009420.KS), a global biopharmaceutical company committed to discovering and developing innovative medicines for patients, reported financial results for 2023 and provided business updates. HanAll delivered a strong full-year performance, with a 23 percent increase in sales compared to 2022, demonstrating continued innovation momentum through multiple meaningful data readouts for anti-FcRn assets and the dry eye disease program. Total revenues for 2023 were 135 billion Korean
Show less
Read more
Impact Snapshot
Event Time:
IMVT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMVT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMVT alerts
High impacting Immunovant, Inc. news events
Weekly update
A roundup of the hottest topics
IMVT
News
- Should You Hold Immunovant (IMVT)? [Yahoo! Finance]Yahoo! Finance
- Here's Why You Should Add Immunovant (IMVT) to Your Portfolio [Yahoo! Finance]Yahoo! Finance
- What Makes Immunovant (IMVT) a New Buy Stock [Yahoo! Finance]Yahoo! Finance
- Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade) [Seeking Alpha]Seeking Alpha
- Immunovant, Inc. (NASDAQ: IMVT) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $50.00 price target on the stock.MarketBeat
IMVT
Earnings
- 2/12/24 - Beat
IMVT
Sec Filings
- 4/26/24 - Form 4
- 4/26/24 - Form 4
- 4/26/24 - Form 4
- IMVT's page on the SEC website